2 recruiting, 2 unknown, 1 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 2, Unknown 2, Completed 1 |
Follow Core Binding Factor Acute Myeloid Leukemia: new trials by email Literature Review of Core Binding Factor Acute Myeloid Leukemia trials Research Report on Core Binding Factor Acute Myeloid Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-10-20 |
| Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation Avapritinib, Azacitidine Injection, Decitabine Injection - AML, Childhood, Relapse/Recurrence | Phase 2 | Recruiting | Children's Hospital of Soochow University | 50 | 2024-03-01 | 2024-08-22 |
| Avapritinib in CBF-AML With KIT Mutations Avapritinib - Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 50 | 2022-06-01 | 2023-05-09 |
| Combination of Sorafenib With Standard Therapy in Newly Diagnosed Adult CBF AML Sorafenib, Idarubicin, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Unknown | Nanfang Hospital, Southern Medical University | 88 | 2020-01-01 | 2022-06-03 |
| Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Cytarabine, Dasatinib, Daunorubicin Hydrochloride - Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Phase 2 | Completed | National Cancer Institute (NCI) | 61 | 2010-12-14 | 2023-03-01 |
Leukemia, Myeloid, Acute (2) · Leukemia, Myelomonocytic, Acute (1) · Recurrence (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Leukemia (2) · Leukemia, Myeloid (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Disease Attributes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
Cytarabine (4) · Daunorubicin (2) · Idarubicin (2) · avapritinib (2) · Azacitidine (1) · Dasatinib (1) · Decitabine (1) · Gemtuzumab (1) · Granulocyte Colony-Stimulating Factor (1) · Sorafenib (1) · Specimen Handling (1) · venetoclax (1)
National Cancer Institute (NCI) (2) · Children's Hospital of Soochow University (1) · Nanfang Hospital, Southern Medical University (1) · The First Affiliated Hospital of Soochow University (1)
China (3) · United States (2) · Puerto Rico (1)
Celalettin Ustun (1) · Guido Marcucci (1) · Qifa Liu (1) · Shaoyan Hu, MD, PhD (1) · Suning Chen (1)
U10CA180821 (2), U10CA031946 (1)